Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 19, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The SPR1NT phase 3 clinical trial—pivotal in pushing the concept of newborn screening for SMA—assessing onasemnogene abeparvovec-xioi in children less than 6 weeks of age is discussed, as well as a recently released integrated safety report.
Scott Newsome, DO, MSCS, FAAN, president of CMSC, offers his perspective on the 2020 Whitaker Lecture from Peter Calabresi, MD.
Over a 2-year stretch, change in monthly migraine days from the double-blind treatment period baseline was sustained in those treated with erenumab.
Peter LeWitt, MD, offers an expert perspective on gastroparesis and its influence on the uptake of oral medication for Parkinson disease.
Impel NeuroPharma, the agent’s developer, is on target for submission of a new drug application for the treatment in the second half of 2020.